Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X6AU
|
||||
| Former ID |
DIB004420
|
||||
| Drug Name |
FAS-031
|
||||
| Synonyms |
FASi; FAS inhibitors (cancer); FAS-031; FAS-093; FAS-31; FAS-93; FAS inhibitors (cancer), FASgen/Johns Hopkins; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins; FAS inhibitors (cancer), FASgen/Johns Hopkins/Johnson & Johnson; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins/ Johnson & Johnson
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Investigative | [543659] | ||
| Company |
Johns Hopkins University
|
||||
| Target and Pathway | |||||
| Target(s) | Fatty acid synthase | Target Info | Inhibitor | [543659] | |
| Pathway Interaction Database | p73 transcription factor network | ||||
| Validated transcriptional targets of deltaNp63 isoforms | |||||
| PathWhiz Pathway | Fatty Acid Biosynthesis | ||||
| WikiPathways | Fatty Acid Biosynthesis | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Liver X Receptor Pathway | |||||
| Activation of Gene Expression by SREBP (SREBF) | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| SREBP signalling | |||||
| Metabolism of water-soluble vitamins and cofactors | |||||
| Integration of energy metabolism | |||||
| Fatty acid, triacylglycerol, and ketone body metabolism | |||||
| AMPK Signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.